Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez. The move leaves no active gene therapy programs in Pfizer's portfolio.
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez. The move leaves no active gene therapy programs in Pfizer's portfolio.
